Description
AOD-9604 is a synthetic peptide fragment derived from amino acids 177-191 of human growth hormone (HGH). In contrast to the complete growth hormone molecule, AOD-9604 in research models exhibits the lipolysis-stimulating properties of the C-terminal HGH end without the growth or insulin sensitivity modulating properties of the full hormone.
The central research mechanism lies in fat metabolism. Preclinical studies have documented that AOD-9604 stimulates hormone-sensitive lipase activity in adipocytes and thereby increases the release of free fatty acids from adipose tissue. At the same time, the compound shows reduced lipogenesis rates in animal models. Beta-3 adrenoreceptor activity is also under discussion, although the mechanisms are not conclusively resolved.
Earlier clinical studies investigated AOD-9604 as a compound in adiposity models. Phase 2 data in human settings were mixed, which prevented the transition into phase 3 trials. AOD-9604 nevertheless remains an established compound in the community for studies on the HGH fragment mechanism.
Per study reports, AOD-9604 is typically applied daily subcutaneously in preclinical setups. The half-life is relatively short, which requires frequent application intervals.
AOD-9604 is available in 5mg vials as 10-vial packs.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
AOD-9604 is considered well tolerated per study reports. Because it represents only the C-terminal HGH fragment, it lacks the growth and insulin sensitivity modulating properties of the full growth hormone, which keeps the risk profile comparatively narrow.
Observed in studies and user reports:
- Injection site: mild redness, pressure or transient irritation at the injection site is the most common observation, particularly with frequent subcutaneous use.
- Circulation: isolated reports of brief warmth, mild dizziness or fatigue shortly after application.
- Mixed efficacy data: the human Phase 2 data were mixed, which prevented the transition into Phase 3 trials. This concerns efficacy rather than primarily the safety profile.
- No long-term data: robust long-term human studies do not exist. The classification rests primarily on animal models and short-term anecdotal experience.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- The effect of growth hormone fragment AOD9604 on weight loss - Obesity 2007: Phase 2 study with 300 participants over 12 weeks.
- The lipolytic action of AOD9604 in 3T3-L1 adipocytes - Journal of Endocrinology 2009: Cell-level mechanism study.
- GH and the regulation of lipolysis - Best Practice & Research Clinical Endocrinology 2008: Overview of HGH fragment mechanism.
